PR
CVS icon

Payden & Rygel’s CVS Health CVS Stock Holding History

Payden & Rygel’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6M Buy
218,700
+5,600
+3% +$500K 1.74% 15
2026
Q1 		$15.3M Sell
213,100
-47,100
-18% -$3.63M 1.18% 32
2025
Q4 		$20.6M Sell
260,200
-1,300
-0.5% -$102K 1.43% 21
2025
Q3 		$19.7M Buy
+261,500
New +$17.9M 1.63% 19
2024
Q4 		– Sell
-99,900
Closed -$6.28M – 128
2024
Q3 		$6.28M Buy
+99,900
New +$5.83M 0.48% 69
2024
Q2 		– Sell
-183,500
Closed -$14.6M – 127
2024
Q1 		$14.6M Sell
183,500
-135,500
-42% -$10.4M 0.69% 57
2023
Q4 		$25.2M Buy
319,000
+35,600
+13% +$2.53M 1.75% 10
2023
Q3 		$19.8M Buy
283,400
+182,000
+179% +$12.9M 1.35% 16
2023
Q2 		$7.01M Buy
101,400
+97,300
+2,373% +$6.92M 0.5% 80
2023
Q1 		$305K Sell
4,100
-432,100
-99% -$36.2M 0.02% 109
2022
Q4 		$40.6M Buy
436,200
+29,000
+7% +$2.8M 2.17% 8
2022
Q3 		$38.8M Buy
407,200
+8,700
+2% +$861K 2.27% 3
2022
Q2 		$36.9M Buy
398,500
+821
+0.2% +$80.1K 2.22% 8
2022
Q1 		$40.2M Sell
397,679
-114,700
-22% -$12M 2.03% 10
2021
Q4 		$52.9M Sell
512,379
-2,200
-0.4% -$203K 2.44% 1
2021
Q3 		$43.7M Buy
514,579
+235,300
+84% +$19.7M 2.27% 4
2021
Q2 		$23.3M Sell
279,279
-147,837
-35% -$12.1M 1.11% 47
2021
Q1 		$32.1M Buy
427,116
+16,716
+4% +$1.22M 1.49% 27
2020
Q4 		$28M Buy
410,400
+128,100
+45% +$8.33M 1.44% 35
2020
Q3 		$16.5M Sell
282,300
-76,600
-21% -$4.77M 0.98% 58
2020
Q2 		$23.3M Sell
358,900
-1,100
-0.3% -$69.3K 1.49% 32
2020
Q1 		$21.4M Buy
360,000
+15,271
+4% +$1.02M 1.54% 31
2019
Q4 		$25.6M Sell
344,729
-250,200
-42% -$17.6M 1.6% 33
2019
Q3 		$37.5M Buy
594,929
+108,129
+22% +$6.41M 2.55% 5
2019
Q2 		$26.5M Buy
486,800
+229,800
+89% +$12.4M 1.82% 20
2019
Q1 		$13.9M Buy
+257,000
New +$15.9M 1.01% 52
2016
Q1 		– Sell
-187
Closed -$18K – 173
2015
Q4 		$18K Buy
+187
New +$18.3K ﹤0.01% 144

Other funds holding CVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Payden & Rygel's CVS Position: Q2 2026 in Review

Payden & Rygel increased its CVS Health (CVS) stake by 2.6% in Q2 2026, buying an estimated $500K and bringing the position to 218,700 shares worth $22.6M. The position accounts for 1.74% of the portfolio, ranked #15.

Payden & Rygel first reported a position in CVS in Q4 2015 and has held it in 27 quarters since. The position peaked at $52.9M in Q4 2021. 2,067 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • Payden & Rygel held 218,700 shares of CVS Health worth $22.6M as of Q2 2026.
  • Payden & Rygel bought 5,600 CVS Health shares in Q2 2026, an estimated $500K.
  • CVS Health made up 1.74% of Payden & Rygel's portfolio in Q2 2026, its #15 holding.
  • Payden & Rygel first reported a position in CVS Health in Q4 2015 and has held it in 27 quarters since.
  • Payden & Rygel's CVS Health position peaked at $52.9M in Q4 2021.
  • 2,067 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on Payden & Rygel's 13F filing for Q2 2026, filed 31 Jul 2026.